New therapy targeting RSK3 to improve heart failure outcomes
RSK3 Anchoring Disruptor Therapy for Heart Failure
This study is testing a new treatment that uses a virus to deliver a special peptide to heart cells, which could help prevent heart failure by stopping harmful changes in the heart, and it aims to improve heart function and quality of life for people with heart issues.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cardiac Rsk3 Inhibitors, LLC NIH-funded |
| Lab location | 1 site (Los Altos, United States) |
| Project ID | NIH-10929421 on NIH RePORTER |
What this research studies
This research investigates a novel therapy aimed at disrupting the interaction between RSK3 and a specific scaffold protein in cardiac cells, which is crucial for preventing heart failure. By using adeno-associated viruses to deliver a peptide that blocks this interaction, the study aims to inhibit pathological remodeling of the heart that occurs during conditions like pressure overload and myocardial infarction. The approach has shown promise in mouse models, suggesting it could lead to improved heart function and quality of life for patients with heart failure.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with heart failure or those at high risk of developing heart failure due to conditions like hypertension or previous heart attacks.
Not a fit: Patients with heart failure caused by non-cardiac factors or those who do not respond to conventional heart failure treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves survival and quality of life for patients with heart failure.
How similar studies have performed: Other research has shown success with similar therapeutic approaches targeting intracellular signaling pathways in heart disease, indicating potential for this novel strategy.
Where this research is happening
Los Altos, United States
- Cardiac Rsk3 Inhibitors, LLC — Los Altos, United States (Active)
Researchers
- Principal investigator: Cividini, Federico — Cardiac Rsk3 Inhibitors, LLC
- Study coordinator: Cividini, Federico
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.